Introduction
The needle-free injection system is a novel technique used to introduce medicines to patients without piercing the skin with conventional needles. This technology offers the benefit of reducing patient concern about the use of needles. These injections are very effective for a wide range of drugs and results in less pain and hence are strongly preferred by patients. Additional benefits of these needle-free injections include fast results as compared to conventional needles and no issue of needle disposal. This technique could be used to administer vaccines and medications in the pork industry. The rising prevalence of various chronic diseases is propelling the need for needle-free injections. Increase in investments in the pharmaceutical sector and convenient use of these medical devices in home care are projected to drive market growth over the forecast period.
However, the high cost of these devices, strict regulatory bodies, and stringent regulatory policies are expected to restrain market growth during the forecast period.
The global needle-free injection market has been segmented, by product, technology, usability, type of medication, site of delivery, application, and end user.
Based on product type, the global needle-free injection market has been categorized as fillable needle-free injectors and prefilled needle-free injectors.
On the basis of technology, the global needle-free injection market is further sub-segmented into jet-based, spring-based, and laser-powered.
By usability, the global needle-free injection market is further sub-segmented into reusable needle-free injectors and disposable needle-free injectors.
The global needle-free injection market by type of medication is further sub-segmented into liquid-based needle-free injectors, powder-based needle-free injectors, and projectile/depot-based needle-free injectors.
On the basis of site of delivery, the global needle-free injection market is further sub-segmented into intradermal injectors, intramuscular injectors, and subcutaneous injectors.
By application, the global needle-free injection market is further sub-segmented into vaccination, insulin delivery, and oncology.
On the basis of end user, the market has been classified as hospitals and clinics, ambulatory surgical centers, and home care settings.
The global needle-free injection market was valued at USD 10,377.7 million in 2017 and is expected to register a CAGR of 15.28 % during the forecast period from 2017 to 2023.
Key Players
Some of the key players in the global needle-free injection market are Antares Pharma Inc., Endo Pharmaceuticals Inc., PharmaJet Inc., Inovio Pharmaceuticals Inc., Medical International Technology Inc., INJEX Pharma GmBH, National Medical Products Inc, European Pharma Group, PenJet Corporation, Valeritas Holdings Inc, Crossject, Mika Medical Co., and D'Antonio Consultants International Inc.
Objectives of the Study
- To provide a detailed analysis of the market structure along with a forecast of various segments and sub-segments of the global needle-free injection market
- To provide insights into factors influencing and affecting market growth
- To provide historical and forecast revenue of market segments and sub-segments with respect to countries
- To provide strategic profiling of key players in the market and comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
- To provide economic factors that influence the global needle-free injection market
- To provide a detailed analysis of the value chain and supply chain of the global needle-free injection market
Target Audience
- Government Research Institutes
- Research and Development (R&D) Companies
- Medical Devices Companies
- Academic Institutes and Universities
Key Findings
- The global needle-free injection market is expected to reach USD 25,057.4 million by 2023 at a CAGR of 15.28 % from 2017 to 2023
- Based on technology, the jet-based needle-free injectors segment holds the largest market share and is expected to reach USD 10,391.3 million by 2023 at a CAGR of 15.90% from 2017 to 2023
- The market in the Americas is expected to account for the largest share of the global needle-free injection market and is projected to reach USD 8,750.7 million by 2023
- The needle-free injection market in Asia-Pacific is projected to be the fastest-growing at a CAGR of 15.74 % from 2017 to 2023
Regional Analysis
- Americas
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Western Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
Table of Contents
1 Report Prologue
2 Market Introduction
- 2.1 Introduction
- 2.2 Assumptions & Limitations
3 Research Methodology
- 3.1 Research Process
- 3.2 Primary Research
- 3.3 Secondary Research
- 3.4 Market Size Estimation
4 Market Dynamics
- 4.1 Introduction
- 4.2 Drivers
- 4.2.1 Increasing prevalence of chronic conditions such as diabetes is estimated to increase the demand
for needle-free injectors
- 4.2.2 Capacity of needle-free injectors to support homecare
- 4.2.3 Growing biopharmaceuticals industry
- 4.2.4 Increasing investments in the market
- 4.2.5 Drivers Impact Analysis
- 4.3 Restraints
- 4.3.1 Risks of Cross Contamination
- 4.3.2 High Cost
- 4.3.3 Restraints Impact Analysis
- 4.4 Opportunity
- 4.4.1 Increasing campaigns of vaccination in developing economies of the Asia Pacific region
- 4.5 Macroeconomic Indicators
5 Market Factor Analysis
- 5.1 Value Chain Analysis
- 5.1.1 R&D & Designing
- 5.1.2 Manufacturing
- 5.1.3 Distribution & Sales
- 5.1.4 Post-Sales Review
- 5.2 Porter's Five Forces Model
- 5.2.1 Bargaining Power of Suppliers
- 5.2.2 Bargaining Power of Buyers
- 5.2.3 Threat of New Entrants
- 5.2.4 Threat of Substitutes
- 5.2.5 Intensity of Rivalry
- 5.3 Investment Opportunities
- 5.4 Pricing Analysis
6 Global Needle Free Injection Market, By Product
- 6.1 Introduction
- 6.2 Fillable Needle-Free Injectors
- 6.3 Prefilled Needle-Free Injectors
7 Global Needle Free Injection Market, By Technology
- 7.1 Introduction
- 7.2 Jet-Based
- 7.3 Spring-Based
- 7.4 Laser-Powered
8 Global Needle Free Injection Market, By Usability
- 8.1 Introduction
- 8.2 Reusable Needle-Free Injectors
- 8.3 Disposable Needle-Free Injectors
9 Global Needle Free Injection Market, By Type of Medication
- 9.1 Introduction
- 9.2 Liquid-Based Needle Free Injectors
- 9.3 Powder-Based Needle Free Injectors
- 9.4 Projectile/Depot-Based Needle Free Injectors
10 Global Needle Free Injection Market, By Site of Delivery
- 10.1 Introduction
- 10.2 Intra dermal injectors
- 10.3 Intramuscular injectors
- 10.4 Subcutaneous injectors
11 Global Needle Free Injection Market, By Application
- 11.1 Introduction
- 11.2 Vaccination
- 11.3 Insulin Delivery
- 11.4 Oncology
12 Global Needle Free Injection Market, By End Users
- 12.1 Introduction
- 12.2 Hospitals and Clinics
- 12.3 Ambulatory Surgical Centres
- 12.4 Homecare Settings
13 Global Needle Free Injection Market, By Region
- 13.1 Introduction
- 13.2 Americas
- 13.2.1 North America
- 13.2.1.1 U.S
- 13.2.1.2 Canada
- 13.2.2 South America
- 13.3 Europe
- 13.3.1 Western Europe
- 13.3.1.1 Germany
- 13.3.1.2 France
- 13.3.1.3 U.K
- 13.3.1.4 Italy
- 13.3.1.5 Spain
- 13.3.1.6 Rest of Western Europe
- 13.3.2 Eastern Europe
- 13.4 Asia Pacific
- 13.4.1 China
- 13.4.2 India
- 13.4.3 Japan
- 13.4.4 South Korea
- 13.4.5 Rest of Asia Pacific
- 13.5 Middle East & Africa
- 13.6 The Middle East
14 Competitive Landscape
- 14.1 Introduction
- 14.2 Recent Developments, 2014-2018
15 Company Profiles
- 15.1 Antares Pharma Inc.
- 15.1.1 Company Overview
- 15.1.2 Financial Overview
- 15.1.3 Products Offering
- 15.1.4 Key Developments
- 15.1.5 SWOT Analysis
- 15.1.6 Key Strategy
- 15.2 Endo Pharmaceuticals Inc.
- 15.2.1 Company Overview
- 15.2.2 Financial Overview
- 15.2.3 Products Offering
- 15.2.4 Key Developments
- 15.2.5 SWOT Analysis
- 15.2.6 Key Strategy
- 15.3 PharmaJet, Inc
- 15.3.1 Company Overview
- 15.3.2 Financial Overview
- 15.3.3 Products Offering
- 15.3.4 Key Developments
- 15.3.5 SWOT Analysis
- 15.3.6 Key Strategy
- 15.4 Inovio Pharmaceuticals Inc.
- 15.4.1 Company Overview
- 15.4.2 Financial Overview
- 15.4.3 Products Offering
- 15.4.4 Key Developments
- 15.4.5 SWOT Analysis
- 15.4.6 Key Strategy
- 15.5 Medical International Technology, Inc.
- 15.5.1 Company Overview
- 15.5.2 Financial Overview
- 15.5.3 Products Offering
- 15.5.4 Key Developments
- 15.5.5 SWOT Analysis
- 15.5.6 Key Strategy
- 15.6 INJEX Pharma GmBH
- 15.6.1 Company Overview
- 15.6.2 Financial Overview
- 15.6.3 Products Offering
- 15.6.4 Key Developments
- 15.6.5 SWOT Analysis
- 15.6.6 Key Strategy
- 15.7 National Medical Products Inc.
- 15.7.1 Company Overview
- 15.7.2 Financial Overview
- 15.7.3 Products Offering
- 15.7.4 Key Developments
- 15.7.5 SWOT Analysis
- 15.7.6 Key Strategy
- 15.8 European Pharma Group
- 15.8.1 Company Overview
- 15.8.2 Financial Overview
- 15.8.3 Products Offering
- 15.8.4 Key Developments
- 15.8.5 SWOT Analysis
- 15.8.6 Key Strategy
- 15.9 PenJet Corporation
- 15.9.1 Company Overview
- 15.9.2 Financial Overview
- 15.9.3 Products Offering
- 15.9.4 SWOT Analysis
- 15.9.5 Key Strategy
- 15.1 Valeritas Holdings, Inc.
- 15.10.1 Company Overview
- 15.10.2 Financial Overview
- 15.10.3 Products Offering
- 15.10.4 Key Developments
- 15.10.5 SWOT Analysis
- 15.10.6 Key Strategy
- 15.11 CROSSJECT
- 15.11.1 Company Overview
- 15.11.2 Financial Overview
- 15.11.3 Products Offering
- 15.11.4 Key Developments
- 15.11.5 SWOT Analysis
- 15.11.6 Key Strategy
- 15.12 MIKA MEDICAL CO.
- 15.12.1 Company Overview
- 15.12.2 Financial Overview
- 15.12.3 Products Offering
- 15.12.4 Key Developments
- 15.12.5 SWOT Analysis
- 15.12.6 Key Strategy
- 15.13 D'Antonio Consultants International, Inc.
- 15.13.1 Company Overview
- 15.13.2 Financial Overview
- 15.13.3 Products Offering
- 15.13.4 Key Developments
- 15.13.5 SWOT Analysis
- 15.13.6 Key Strategy
16 Appendix
- 16.1 Discussion Blue Print
比較リスト
